New SPECT method could reveal hidden heart issues in amyloidosis patients

NCT ID NCT05103943

Ongoing Knowledge-focused Sponsor: Centre Hospitalier Régional d'Orléans Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 50 people with TTR amyloid cardiomyopathy, a condition where abnormal proteins build up in the heart. Researchers want to see if a special SPECT scan can measure blood flow in the heart's tiny vessels, which may be impaired even without blocked arteries. Participants will have two scans 24 months apart to track changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors better understand and monitor heart blood flow problems in TTR amyloidosis patients using widely available SPECT technology.
What could go wrong: This is a small observational study (50 people) with no treatment being tested. It only measures blood flow, so it won't directly improve patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOID CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies, Familial restrictive cardiomyopathy wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLOID CARDIOMYOPATHY

Contacts and locations

Locations

CHRU de TOURS

Tours, France
CHU Caen

Caen, 14033, France
CHU Orleans

Orléans, 45067, France
CHU d'ANGERS

Angers, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.